DACOGEN 50 MG LYOPH. PD. FOR IV INF

Indication For treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated de novo and secondary MDS of all French-American-British subtypes (refractory anemia refractory anemia with ringed sideroblasts refractory anemia with excess blasts refractory anemia with excess blasts in transformation and chronic myelomonocytic leukemia) and intermediate-1 intermediate-2 and high-risk International Prognostic Scoring System groups (scores =0.5).